Trial Profile

Anidulafungin to replace caspofungin in the treatment of fungal infections in cancer patients.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anidulafungin (Primary)
Indications Candidaemia; Candidiasis; Systemic mycoses
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
07 Sep 2015 New trial record
25 Aug 2015 Results published in the Journal of Antimicrobial Chemotherapy.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com